Activation, proliferation and commitment of endogenous stem/progenitor cells to the oligodendrocyte lineage by TS1 in a rat model of dysmyelination.

TitleActivation, proliferation and commitment of endogenous stem/progenitor cells to the oligodendrocyte lineage by TS1 in a rat model of dysmyelination.
Publication TypeJournal Article
Year of Publication2006
AuthorsEspinosa-Jeffrey, A, Zhao P, Awosika W, Wu N, Macias F, Cepeda C, Levine M, de Vellis J
JournalDevelopmental neuroscience
Volume28
Issue6
Pagination488-98
Date Published2006
ISSN0378-5866
KeywordsAnimals, Animals, Newborn, Biological Markers, Cell Differentiation, Cell Lineage, Cell Movement, Cell Proliferation, Central Nervous System, Corpus Callosum, Demyelinating Diseases, Disease Models, Animal, Glial Fibrillary Acidic Protein, Insulin-Like Growth Factor I, Intermediate Filament Proteins, Lateral Ventricles, Male, Nerve Tissue Proteins, Neurofilament Proteins, Oligodendroglia, Rats, Rats, Mutant Strains, Rats, Wistar, Stem Cells, Telencephalon, Transferrin
Abstract

Wild-type and myelin-deficient rats received a single intraparenchymal injection of TS1, a specific combination of IGF-1 and transferrin (Tf), into their corpus callosum at postnatal day 4. The fate of endogenous stem cells in the brain was examined by the expression of the stem cell marker nestin, together with Tf, neurofilaments and glial fibrillary acidic protein from 2 to 14 days after injection. Treated mutants lacked nestin expression in the ventricular wall and had an increase in nestin-labeled radial cell processes in the subventricular regions, and extended into the parenchyma. The subventricular zone was populated by healthy new oligodendrocytes (OLs). BrdU incorporation showed that these cells originated by proliferation and were identified as OLs based upon Tf expression. Thus, TS1 is an effective treatment to promote endogenous subventricular zone progenitor proliferation, migration and OL lineage specification. This strategy offers for the first time the possibility of myelin restoration to treat myelin disorders.

DOI10.1042/AN20110027
Alternate JournalDev. Neurosci.